Novel C5a regulators in inflammatory disease.
Complement is part of the innate immune system, acting to protect the host from microorganisms such as bacteria, and other foreign and abnormal cells. Although primarily protective, complement activation can also cause damage to the host. In a number of inflammatory diseases, including rheumatoid arthritis and dermatitis, there is excessive and inappropriate complement activation. Many of the toxic effects seen in these conditions are attributable to the excessive production of the anaphylatoxin C5a, which may contribute to both the initiation and progression of the disease. Therefore, the regulation of C5a production and modulation of its function are good pharmacological targets in these disorders. As yet, there are no effective agents for the therapeutic regulation of C5a in routine clinical practice. This review describes the role of C5a in inflammatory disease, animal models used to study C5a-related effects, and current strategies aimed at regulating C5a. There is also a discussion of the strengths and weaknesses of these approaches, and an outline of the likely progress of this class of drugs in the future.
Mizuno
Masashi
M
Department of Medical Biochemistry and Immunology, Cardiff University, School of Medicine, Henry Wellcome Building, Heath Park, Cardiff CF14 4XN, UK. MizunoM1@cardiff.ac.uk
Cole
Duncan S
DS
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D003167:Complement Activation / Q000187:drug effects; D015936:Complement C5a / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004195:Disease Models, Animal; D016503:Drug Delivery Systems / Q000379:methods; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D018836:Inflammation Mediators / Q000008:administration & dosage* / Q000737:chemistry
D015507:Drugs, Investigational; D018836:Inflammation Mediators; D015936:Complement C5a